Research Article
Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
Table 3
Prevalence depending on trial subset (RAKET or Satellite).
| | | RAKET | | | Satellite | | EGFRmut | EGFR FISHpos | KRASmut | EGFRmut | EGFR FISHpos |
| = | 2* | 2** | 11 | 3† | 10†† | 8 | Inconclusive | 2 | 5 | 3 | | 3 | | Median age | 69, 71 | 69, 75 | 60 (55–73)
| 47, 54, 62 | 62 (43–68) | 62 (60–67) | Gender F/M | F, F | F, M | 55/45% | F, M, M | 70/30% | 62/38% | PS 0/1 | 1, 1 | 1, 1 | 45/55% | 1, 0, 0 | 60/40% | 50/50% | Stage IIIA/IIIB | IIIB, IIIB | IIIB, IIIB | 18/82% | IIIA, 2IIIB | 20/80% | 25/75% | Weight loss > 5% | 0 | 0, 1 | 27% | 0, 0, 1 | 40% | 37% | Histology: | | | | | | | Adenocarcinoma | 100% | 100% | 64% | 0% | 30% | 75% | SCC | 0% | 0% | 18% | 67% | 50% | 0% | NSCLC NUS | 0% | 0% | 18% | 33% | 20% | 25% |
|
|
*
del 19 and L858R (exon 21).
**one overlapping with EGFRmut L858R. †G719X (exon 18). ††two overlapping with KRASmut and one with G719X.
|